Lantern Pharma Inc.

NasdaqCM:LTRN Stock Report

Market Cap: US$33.7m

Lantern Pharma Future Growth

Future criteria checks 0/6

Lantern Pharma's earnings are forecast to decline at 3.8% per annum. EPS is expected to grow by 15.7% per annum.

Key information

-3.8%

Earnings growth rate

15.7%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated12 Nov 2024

Recent future growth updates

Recent updates

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Nov 05
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jun 12
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Nov 06
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jul 20
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Apr 04
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Dec 19
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Sep 02
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Jul 14

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

May 20
Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Feb 02
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Oct 13
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Aug 24

Lantern Pharma: Drug Recycling With AI

Jun 08

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

May 05
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma reports Q1 results

May 03

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Feb 19
Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Jan 04

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Lantern: Early Stage 'Smart Drug' Discovery Company

Nov 25

Earnings and Revenue Growth Forecasts

NasdaqCM:LTRN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-19N/AN/A1
12/31/2025N/A-25N/AN/A2
12/31/2024N/A-21N/AN/A2
9/30/2024N/A-19-17-17N/A
6/30/2024N/A-18-15-15N/A
3/31/2024N/A-18-14-14N/A
12/31/2023N/A-16-14-14N/A
9/30/2023N/A-15-14-14N/A
6/30/2023N/A-14-14-14N/A
3/31/2023N/A-14-13-13N/A
12/31/2022N/A-14-13-13N/A
9/30/2022N/A-14-12-12N/A
6/30/2022N/A-16-13-13N/A
3/31/2022N/A-14-12-12N/A
12/31/2021N/A-12-11-11N/A
9/30/2021N/A-12-10-10N/A
6/30/2021N/A-9-8-8N/A
3/31/2021N/A-8-7-7N/A
12/31/2020N/A-6-6-6N/A
9/30/2020N/A-4-5-5N/A
6/30/2020N/A-3-2-2N/A
3/31/2020N/A-2-2-2N/A
12/31/2019N/A-2-2-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LTRN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LTRN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LTRN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if LTRN's revenue is forecast to grow faster than the US market.

High Growth Revenue: LTRN is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LTRN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 09:20
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lantern Pharma Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserColliers Securities
Ashok KumarThinkEquity LLC
John VandermostenZacks Small-Cap Research